Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Discovery themes featuring this stockDiscovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Alkem Laboratories Ltd (ALKEM) is currently trading at 5,374.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others). Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution. Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years. R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas. Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.
Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹4,498.90 and a high of ₹5,933.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alkem Laboratories Ltd has a market capitalization of approximately 65,330.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alkem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.20 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 65,330.91 Cr, Alkem Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alkem Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 27.20. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a new scheme with a ₹10,000 crore outlay over five years aimed at making India a global manufacturing hub for biologics and biosimilars by strengthening the domestic R&D and production ecosystem.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
910.05 | 91,572 Cr | 17.91 | 3.62 | 1.21 | 19.44 | 19.08 | 10.52 | |
2072.00 | 85,665 Cr | 46.03 | 5.60 | 0.00 | 11.45 | 12.34 | 6.26 | |
1171.20 | 67,358 Cr | 19.26 | 1.92 | 0.00 | 9.77 | 12.69 | 6.63 | |
5463.60 | 65,331 Cr | 27.20 | 4.90 | 0.82 | 17.69 | 18.13 | 11.95 | |
2025.00 | 57,267 Cr | 21.11 | 5.98 | 0.12 | 26.24 | 30.84 | 5.60 | |
1039.50 | 56,021 Cr | 66.55 | 11.66 | 0.12 | 14.23 | 15.05 | 8.94 | |
1480.15 | 37,818 Cr | 35.61 | 5.09 | 0.27 | 13.33 | 17.89 | 7.73 |
Investor Presentation
Alkem Laboratories filed an updated investor presentation (18‑Feb‑2026) outlining Alkem MedTech’s strategy to enter MedTech (orthopaedics, cardiovascular, IVD/wound care), launch timelines (knee Q2 FY27, hip Q4 FY27), regulatory/CE targets, manufacturing buildout, and five‑year growth targets (250k+ implants, ~10% India share, global expansion).
Investor Presentation
Alkem Laboratories filed an investor presentation and will host an investor meet on Feb 18, 2026 outlining Alkem MedTech’s launch plans, target segments (ortho, cardiovascular, IVD), manufacturing, approvals and 5‑year growth targets.
Earnings Call Transcript
Alkem reported Q3 FY26 revenue of INR37,368mn (+10.7% YoY), EBITDA INR8,280mn (22.2% margin) and net profit INR6,360mn (+1.6%); announced entry/major investment into MedTech with INR200–300cr capex and ~INR1,000cr 3–5yr revenue target.
USFDA Inspection
USFDA completed a Pre‑Approval Inspection at Enzene Biosciences (Chakan, Pune) on 13 Feb 2026; issued a Form 483 with six procedural observations, noted zero data‑integrity findings, and Enzene is preparing a response and CAPAs.
Regulatory Filing
USFDA completed a Pre‑Approval Inspection at Enzene Biosciences (subsidiary), issued a Form 483 with six procedural observations (none related to data integrity); Enzene will submit responses and corrective actions.
USFDA Inspection
Alkem’s subsidiary Enzene underwent a USFDA Pre‑Approval Inspection resulting in a Form 483 with six procedural observations, zero data‑integrity findings; Enzene will submit a response and has initiated CAPA.
Bearish
2
Neutral
4
Bullish
8
Bearish
33
Neutral
4
Bullish
9
Bearish
31
Neutral
0
Bullish
1
Alkem Laboratories Limited is a Mumbai-headquartered integrated pharmaceutical company that develops, manufactures and sells branded generics, generic formulations, APIs, biosimilars and nutraceuticals in India and internationally, supported by 18 manufacturing facilities, R&D centres and a growing subsidiary ecosystem (Enzene, Alkem MedTech, Ascend, Pharmacor and others).
Q3 FY26 results showed resilient performance: consolidated revenue of ₹37,368 million (+10.7% YoY), EBITDA ₹8,280 million at a 22.2% margin and PAT of ₹6,360 million, while international businesses grew 26.6% YoY led by the US and non‑US markets, signalling successful portfolio and geographic execution.
Strategic expansion into MedTech was announced via a binding term sheet to acquire majority stake in Occlutech, giving Alkem immediate presence in minimally invasive cardiac implants and a high‑value device pipeline, with management projecting Alkem MedTech to become a meaningful growth and margin contributor over the next 3–5 years.
R&D and pipeline depth are notable: Alkem disclosed 188 ANDA filings and 167 approvals (including tentative), ongoing NDAs/BLAs, Q3 R&D spend of ₹1,390 million (3.7% of sales) and planned GLP‑1 semaglutide domestic launch in March 2026, highlighting biologics and specialty chronic therapies as focus areas.
Balance sheet strength and regulatory progress underpin optionality: net cash of ₹55.9 billion as of Dec 31, 2025, multiple facilities with recent EIRs or clean inspection outcomes, and an active ANDA approval cadence that supports US growth and cross‑border expansion.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
65,331 Cr
Low Risk
27.2
26.5
5.9
4.9
5,933.00
4,498.90
Sales CAGR
Profit CAGR
ROE
ROCE
